ClinicalTrials.gg
SuspendedNCT06511284Updated Nov 13, 2026

Nutritional Therapy in Patients With Post-extubation Dysphagia

An interventional study of High protein dose and Usual protein dose in Dysphagia, sponsored by National Institute of Respiratory Diseases, Mexico. Suspended at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by National Institute of Respiratory Diseases, Mexico · Not applicable, Interventional, and Treatment

How we know

Why this study was suspended
The randomized clinical trial was discontinued due to an insufficient recruitment rate, which made it impossible to achieve the estimated sample size. Only four patients had been enrolled to date, resulting in insufficient statistical power
Updated Nov 13, 2026Now SuspendedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate the impact of the prescription of two doses of protein on the amount in kilograms of muscle mass and on the clinical evolution (time until safe swallowing, time until removal of the feeding stoma, number of hospital readmissions, feeding stoma infections, incidence of pneumonia, functionality, number of falls, fractures and mortality) at 6 months after hospital discharge in patients with enteral nutrition due to post-extubation dysphagia.

02

Conditions studied

  • Dysphagia

Browse trials for

Keywords

  • enteral nutrition
  • nutritional assessment
  • nutritional therapy
  • Deglutition Disorders
  • rehabilitation
03

In context

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

This study's planned enrollment of 128 is above the median of 60 across 581 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

National Institute of Respiratory Diseases, Mexico is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who required invasive mechanical ventilation during their hospital stay with a diagnosis of post-extubation dysphagia diagnosed by fibroendoscopy evaluation of swallowing (FEES).
  • Patients who discharged with a feeding tube.
  • Patients with signed .

Exclusion criteria

Exclusion Criteria:

  • Patients with pre-existing dysphagia, or with neurological conditions that can cause dysphagia (e.g. multiple sclerosis, Parkinson's disease, Alzheimer's, myasthenia gravis).
  • Patients with chronic kidney disease, defined as a \<60 ml/min.
  • Patients discharged with a terminal condition and/or of less than 3 months.
  • Diagnosis of , upon receiving clinical follow-up by the team of specialists.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    High protein group

    100% of the energy requirements measured by indirect calorimetry (IC) or estimated, and a protein intake of 2.0 g/kg, will be prescribed

    Other: High protein dose

  • Other
    Usual protein group

    100% of the energy requirements measured by IC or estimated, and a protein intake of 1.5 g/kg, will be prescribed.

    Other: Usual protein dose

Interventions

  • OtherHigh protein dose

    High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition

  • OtherUsual protein dose

    Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition

06

What researchers measure

Primary outcomes

  1. Muscle mass changes

    Changes of muscle mass in kilograms measured by impedance bioelectric

    Time frame: From randomization to 6 months

Secondary outcomes

  1. Swallow recovery

    Time to safe swallowing diagnosed by fibroendoscopy evaluation of swallowing (FEES) and measured in months

    Time frame: From randomization to 6 months

  2. Duration of enteral nutrition indication

    Time from discharge to feeding tube removal

    Time frame: From randomization to 6 months

  3. Feeding tube complications

    Number of feeding tube infections, dysfunctions and oclusions during study period

    Time frame: From randomization to 6 months

  4. Muscle functionality changes

    Changes in functionality measured by medical research council scale in a scale of 0-60 points

    Time frame: From randomization to 6 months

  5. Handgrip strenght changes

    Changes in functionality assessed by handgrip strenght in kilogramos using a digital dynamometer

    Time frame: From randomization to 6 months

  6. Frailty complications

    Number of falls and fractures during study period

    Time frame: From randomization to 6 months

  7. Hospital readmissions associated to dysphagia complications

    Number of hospital readmissions assocciated to feeding tube infections, dysfunctions and oclusions during study period

    Time frame: From randomization to 6 months

  8. 6-month mortality

    All-cause mortality during study period

    Time frame: From randomization to 6 months

  9. Aspiration pneumonia incidence

    Number of hospital readmissions due to aspiration pneumonia

    Time frame: From randomization to 6 months

07

Study locations

1 site
  • National Institute of Respiratory Diseases
    Mexico City, 14080, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 19, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 1, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended The randomized clinical trial was discontinued due to an insufficient recruitment rate, which made it impossible to achieve the estimated sample size. Only four patients had been enrolled to date, resulting in insufficient statistical power
changed Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Suspended
    Why stopped The randomized clinical trial was discontinued due to an insufficient recruitment rate, which made it impossible to achieve the estimated sample size. Only four patients had been enrolled to date, resulting in insufficient statistical power
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06511284
Lead sponsor
National Institute of Respiratory Diseases, Mexico
Responsible party
Ivan Armando Osuna Padilla (Clinical Nutrition Manager, National Institute of Respiratory Diseases, Mexico) — Principal investigator
First posted
Jul 19, 2024
Start date
Jul 1, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Ivan A Osuna-Padilla, PhD
principal investigator · Instituto Nacional de Enfermedades Respiratorias

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion